JOP20220125A1 - مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها - Google Patents
مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامهاInfo
- Publication number
- JOP20220125A1 JOP20220125A1 JOP/2022/0125A JOP20220125A JOP20220125A1 JO P20220125 A1 JOP20220125 A1 JO P20220125A1 JO P20220125 A JOP20220125 A JO P20220125A JO P20220125 A1 JOP20220125 A1 JO P20220125A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- dysaturase
- delta
- inhibitors
- methods
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939821P | 2019-11-25 | 2019-11-25 | |
| PCT/US2020/062020 WO2021108408A1 (en) | 2019-11-25 | 2020-11-24 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220125A1 true JOP20220125A1 (ar) | 2023-01-30 |
Family
ID=73855555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2022/0125A JOP20220125A1 (ar) | 2019-11-25 | 2020-11-24 | مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11512097B2 (enExample) |
| EP (1) | EP4065223A1 (enExample) |
| JP (2) | JP7254246B2 (enExample) |
| KR (2) | KR20230154292A (enExample) |
| CN (2) | CN118161500A (enExample) |
| AR (1) | AR120556A1 (enExample) |
| AU (1) | AU2020392087B2 (enExample) |
| BR (1) | BR112022010054A2 (enExample) |
| CA (1) | CA3162281A1 (enExample) |
| CL (2) | CL2022001357A1 (enExample) |
| CO (1) | CO2022008690A2 (enExample) |
| CR (1) | CR20220308A (enExample) |
| IL (1) | IL293191B2 (enExample) |
| JO (1) | JOP20220125A1 (enExample) |
| MX (1) | MX2022006281A (enExample) |
| PE (1) | PE20231097A1 (enExample) |
| PH (1) | PH12022551282A1 (enExample) |
| SA (1) | SA522432710B1 (enExample) |
| TW (2) | TWI867822B (enExample) |
| UY (1) | UY38971A (enExample) |
| WO (1) | WO2021108408A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11220510B2 (en) * | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| CR20220308A (es) * | 2019-11-25 | 2022-08-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
| CN115557903A (zh) * | 2022-09-27 | 2023-01-03 | 山东潍坊润丰化工股份有限公司 | 一种特草定的制备方法 |
| JP2026500099A (ja) | 2022-11-23 | 2026-01-06 | アムジエン・インコーポレーテツド | Ｆａｄｓ－１阻害剤を使用するｆａｄｓ１媒介性の疾患又は障害の処置のための患者の選択 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3130633A1 (de) | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide |
| ES2058069T3 (es) | 1986-04-07 | 1994-11-01 | Kumiai Chemical Industry Co | Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado. |
| BR9713863A (pt) | 1996-12-05 | 2000-03-14 | Amgen Inc | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processos de profilaxia ou tratamento, para abaixar as concentrações no plasma, para diminuir a produção de prostaglandinas, e, para diminuir a atividade de enzima ciclooxigenase |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| EP1220857B1 (en) | 1999-10-15 | 2005-09-21 | Neurocrine Biosciences, Inc. | Gonadotropin releasing hormone receptor antagonists and their related methods of use |
| US6537998B1 (en) * | 1999-10-15 | 2003-03-25 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| TW200401770A (en) | 2002-06-18 | 2004-02-01 | Sankyo Co | Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof |
| JP2004107228A (ja) | 2002-09-17 | 2004-04-08 | Nippon Nohyaku Co Ltd | 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤 |
| PE20051089A1 (es) | 2004-01-22 | 2006-01-25 | Novartis Ag | Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| US7906645B2 (en) | 2004-12-24 | 2011-03-15 | Astrazeneca Ab | Heterocyclic compounds as ccr2b antagonists |
| ATE474829T1 (de) | 2005-06-27 | 2010-08-15 | Amgen Inc | Entzündungshemmende arylnitrilverbindungen |
| WO2007027012A1 (en) | 2005-07-18 | 2007-03-08 | Samsung Electronics Co., Ltd. | Video coding method and apparatus for reducing mismatch between encoder and decoder |
| CN101227819A (zh) | 2005-07-27 | 2008-07-23 | 巴斯福股份公司 | 杀真菌剂5-甲基-6-苯基三唑并嘧啶基胺 |
| MX2008001059A (es) | 2005-07-27 | 2008-03-19 | Basf Ag | Fungicidas de 6-fenil-pirazolopirimidina-7-ilamina. |
| US20080200480A1 (en) | 2005-07-27 | 2008-08-21 | Basf Aktiengesellschaft | Fungicidal 6-Phenyltriazolopyrimidinylamines |
| CN101360499B (zh) | 2005-10-06 | 2015-10-07 | 默沙东公司 | 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途 |
| EP2074127A1 (en) | 2006-09-28 | 2009-07-01 | Novartis AG | Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use |
| KR20090057416A (ko) | 2006-10-05 | 2009-06-05 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 스테아로일 ＣｏＡ 탈포화효소 억제제로서 사용하기 위한, 바이시클릭 질소 함유 헤테로시클릭 화합물 |
| US8173661B2 (en) | 2006-11-08 | 2012-05-08 | The Rockefeller University | Alpha-IIB-beta-3 inhibitors and uses thereof |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| WO2008087182A2 (de) | 2007-01-19 | 2008-07-24 | Basf Se | Fungizide mischungen aus 1-methylpyrazol-4-ylcarbonsäureaniliden und azolopyrimidinylaminen |
| EP2131658A2 (en) | 2007-01-30 | 2009-12-16 | Basf Se | Method for improving plant health |
| US8461077B2 (en) | 2007-03-23 | 2013-06-11 | Basf Se | Combinations of active substances |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009124259A1 (en) | 2008-04-04 | 2009-10-08 | Cv Therapeutics, Inc. | Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| US20100099561A1 (en) | 2008-10-15 | 2010-04-22 | E.I. Du Pont De Nemours And Company | Heterobicyclic alkylthio-bridged isoxazolines |
| WO2010087467A1 (en) | 2009-01-27 | 2010-08-05 | Takeda Pharmaceutical Company Limited | Delta-5-desaturase inhibitors |
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| WO2011114148A1 (en) * | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
| WO2012011592A1 (ja) | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US8952012B2 (en) | 2012-05-24 | 2015-02-10 | Colorado State University Research Foundation | Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease |
| EP2970307B1 (en) | 2013-03-13 | 2020-03-11 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| US9505767B2 (en) | 2013-09-05 | 2016-11-29 | Genentech, Inc. | Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors |
| WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| WO2015135094A1 (en) | 2014-03-13 | 2015-09-17 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| JP6442485B2 (ja) | 2014-04-23 | 2018-12-19 | 田辺三菱製薬株式会社 | 新規二環性または三環性複素環化合物 |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| JP6791717B2 (ja) | 2015-10-22 | 2020-11-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP2017091808A (ja) | 2015-11-10 | 2017-05-25 | 株式会社フジクラ | 酸化物超電導線材の製造方法及び超電導コイルの製造方法 |
| WO2017112678A1 (en) | 2015-12-21 | 2017-06-29 | Rima Mcleod | Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases |
| SG11201901747VA (en) | 2016-08-31 | 2019-03-28 | Agios Pharmaceuticals Inc | Inhibitors of cellular metabolic processes |
| WO2018039972A1 (en) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| CN106749271B (zh) * | 2016-12-07 | 2019-04-05 | 青岛科技大学 | 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途 |
| SG11201910197SA (en) | 2017-05-15 | 2019-11-28 | Dana Farber Cancer Inst Inc | Compounds for treating dengue virus infection and other viral infections |
| WO2018229683A1 (en) | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| MX2020002869A (es) | 2017-09-15 | 2020-07-24 | Aduro Biotech Inc | Compuestos de pirazolopirimidinona y usos de los mismos. |
| CR20220308A (es) * | 2019-11-25 | 2022-08-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso |
-
2020
- 2020-11-24 CR CR20220308A patent/CR20220308A/es unknown
- 2020-11-24 KR KR1020237037455A patent/KR20230154292A/ko not_active Ceased
- 2020-11-24 MX MX2022006281A patent/MX2022006281A/es unknown
- 2020-11-24 CN CN202410291075.3A patent/CN118161500A/zh active Pending
- 2020-11-24 BR BR112022010054A patent/BR112022010054A2/pt unknown
- 2020-11-24 CN CN202080081465.8A patent/CN114728167B/zh active Active
- 2020-11-24 PH PH1/2022/551282A patent/PH12022551282A1/en unknown
- 2020-11-24 PE PE2022000849A patent/PE20231097A1/es unknown
- 2020-11-24 JO JOP/2022/0125A patent/JOP20220125A1/ar unknown
- 2020-11-24 CA CA3162281A patent/CA3162281A1/en active Pending
- 2020-11-24 IL IL293191A patent/IL293191B2/en unknown
- 2020-11-24 US US17/103,389 patent/US11512097B2/en active Active
- 2020-11-24 EP EP20828193.1A patent/EP4065223A1/en active Pending
- 2020-11-24 WO PCT/US2020/062020 patent/WO2021108408A1/en not_active Ceased
- 2020-11-24 JP JP2022529556A patent/JP7254246B2/ja active Active
- 2020-11-24 KR KR1020227021152A patent/KR102598203B1/ko active Active
- 2020-11-24 AU AU2020392087A patent/AU2020392087B2/en active Active
- 2020-11-25 AR ARP200103274A patent/AR120556A1/es unknown
- 2020-11-25 TW TW112142068A patent/TWI867822B/zh active
- 2020-11-25 UY UY0001038971A patent/UY38971A/es not_active Application Discontinuation
- 2020-11-25 TW TW109141315A patent/TWI815061B/zh active
-
2021
- 2021-03-16 US US17/203,457 patent/US20210221824A1/en not_active Abandoned
-
2022
- 2022-05-24 SA SA522432710A patent/SA522432710B1/ar unknown
- 2022-05-24 CL CL2022001357A patent/CL2022001357A1/es unknown
- 2022-06-22 CO CONC2022/0008690A patent/CO2022008690A2/es unknown
- 2022-11-18 US US18/056,863 patent/US12448396B2/en active Active
-
2023
- 2023-03-27 JP JP2023049452A patent/JP7698676B2/ja active Active
- 2023-08-22 CL CL2023002486A patent/CL2023002486A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100208B (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| JOP20220125A1 (ar) | مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| MX2020009956A (es) | Compuestos para el tratamiento de enfermedad de hungtinton. | |
| PH12020551464A1 (en) | Cd73 inhibitors | |
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
| EA201100136A1 (ru) | 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| UA108369C2 (uk) | Піролопіримідини як інгібітори cdk4/6 | |
| PH12021500034A1 (en) | Compounds useful in hiv therapy | |
| EA202091803A1 (ru) | Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) | |
| UA107784C2 (en) | Inhibitor of melanin production | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| EA202091804A1 (ru) | Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| MY197064A (en) | Oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors | |
| MX2020007152A (es) | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. | |
| PH12021550374A1 (en) | Small molecule menin inhibitors | |
| MX2022006370A (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso. | |
| ZA202400821B (en) | Inhibitors of transglutaminases | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| EA201200764A1 (ru) | Производные хиназолина |